Compare UBSI & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UBSI | LQDA |
|---|---|---|
| Founded | 1982 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 5.5B |
| IPO Year | 1994 | 2020 |
| Metric | UBSI | LQDA |
|---|---|---|
| Price | $46.49 | $34.44 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 8 |
| Target Price | $50.33 | ★ $54.38 |
| AVG Volume (30 Days) | 941.0K | ★ 4.6M |
| Earning Date | 10-30-2026 | 11-02-2026 |
| Dividend Yield | ★ 3.26% | N/A |
| EPS Growth | 18.91 | ★ 51.81 |
| EPS | ★ 1.83 | 1.26 |
| Revenue | ★ $311,957,000.00 | $158,320,000.00 |
| Revenue This Year | $4.25 | $357.27 |
| Revenue Next Year | $3.88 | $1.34 |
| P/E Ratio | ★ $25.52 | $27.38 |
| Revenue Growth | N/A | ★ 1031.18 |
| 52 Week Low | $34.68 | $21.97 |
| 52 Week High | $49.62 | $93.61 |
| Indicator | UBSI | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 49.96 | 35.01 |
| Support Level | $46.28 | $32.63 |
| Resistance Level | $47.18 | $42.62 |
| Average True Range (ATR) | 0.77 | 2.81 |
| MACD | 0.11 | 0.60 |
| Stochastic Oscillator | 64.80 | 25.40 |
United Bankshares Inc is a financial holding company that provides banking services. The company operates in one segment: Community banking, which offers a full range-of-products and services through various delivery channels. Included among the banking products and services offered are the acceptance of deposits in checking, savings, time, and money market accounts; the making and servicing of personal, credit card, commercial, and floor plan loans; and the making of construction and real estate loans, as well as the origination and sale of residential mortgages in the secondary market. Also offered are trust and brokerage services, safe deposit boxes, and wire transfers.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.